Thomas Zeyen

Thomas Zeyen

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2021 in Translational Stroke Research
Verified
Journal Article
Open access
PDF file
OHOle Heinisch
Ole Heinisch
TZThomas Zeyen
Thomas Zeyen
TGTobias Goldmann
Tobias Goldmann
MPMarco Prinz
Marco Prinz
MHMichael Huber
Michael Huber
PHPardes Habib
Pardes Habib
Inflammasomes are known to contribute to brain damage after acute ischemic stroke (AIS). TAK1 is predominantly expressed in microglial cells and can regulate the NLRP3 inflammasome, but its impact on other inflammasomes including NLRC4 and AIM2 after AIS remains elusive. EPO has been shown to reduce NLRP3 protein levels in different disease models. Whether EPO-mediated neuroprotection after AIS is conveyed via an EPO/TAK1/inflammasome axis in microglia remains to be clarified. Subjecting mice deficient for TAK1 in microglia/macrophages (Mi/MΦ) to AIS revealed a significant reduction in infarct sizes and neurological impairments compared to the corresponding controls. Post-ischemic increased activation of TAK1, NLRP3, NLRC4, and AIM2 inflammasomes including their associated downstream cascades were markedly reduced upon deletion of Mi/MΦ TAK1. EPO administration improved clinical outcomes and dampened stroke-induced activation of TAK1 and inflammasome cascades, which was not evident after the deletion of Mi/MΦ TAK1. Pharmacological inhibition of NLRP3 in microglial BV-2 cells did not influence post-OGD IL-1β levels, but increased NLRC4 and AIM2 protein levels, suggesting compensatory activities among inflammasomes. Overall, we provide evidence that Mi/MΦ TAK1 regulates the expression and activation of the NLRP3, NLRC4, AIM2 inflammasomes. Furthermore, EPO mitigated stroke-induced activation of TAK1 and inflammasomes, indicating that EPO conveyed neuroprotection might be mediated via an EPO/TAK1/inflammasome axis. Graphical Abstract

17 January 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
JLJulian P. Layer
Julian P. Layer
KLKatharina Layer
Katharina Layer
GSGustavo R. Sarria
Gustavo R. Sarria
FRFred Röhner
Fred Röhner
CDCas S. Dejonckheere
Cas S. Dejonckheere
LSLeonard Christopher Schmeel
Leonard Christopher Schmeel
Purpose: To determine the safety and outcome profile of five-fraction stereotactic radiotherapy (FSRT) for brain metastases (BM), either as a definitive or adjuvant treatment. Methods: We assessed clinical data of patients receiving five fractions of 7 Gy each (cumulative physical dose of 35 Gy) to BM or surgical cavities. The primary endpoints were toxicity and radiation necrosis (RN) rates. Secondary endpoints were 1-year cumulative local control rate (LCR) and estimated overall survival (OS). Results: A total of 36 eligible patients receiving FSRT to a total of 49 targets were identified and included. The median follow up was 9 (1.1–56.2) months. The median age was 64.5 (34–92) years, the median ECOG score was 1, and the median Diagnostic-Specific Graded Prognostic Assessment (DS-GPA) score was 2. Treatment was well tolerated and there were no grade 3 adverse events or higher. The overall RN rate was 14.3% and the median time to RN was 12.9 (1.8–23.8) months. RN occurrence was associated with immunotherapy, young age (≤45 years), and large PTV. The cumulative 1-year local control rate was 83.1% and the estimated median local progression free-survival was 18.8 months. The estimated median overall survival was 11 (1.1–56.2) months and significantly superior in those patients presenting with RN. Conclusions: FSRT with 5 × 7 Gy represents a feasible, safe, and efficient fast track approach of intensified FSRT with acceptable LC and comparable RN rates for both the adjuvant and definitive RT settings.

6 January 2025 in Neuro-Oncology Advances
Verified
Journal Article
Open access
TZThomas Zeyen
Thomas Zeyen
ATAntonia Treiber
Antonia Treiber
Matthias SchneiderMatthias Schneider
Matthias Schneider
APAnna-Laura Potthoff
Anna-Laura Potthoff
CSChristina Schaub
Christina Schaub
JWJohannes Weller
Johannes Weller
Background: The optimal salvage therapy for recurrent MGMT-methylated glioblastoma (GBM), IDH wildtype, remains undefined. While lomustine is often used in clinical trials and considered standard-of-care, cumulative toxicity precludes its use in patients previously treated with lomustine/temozolomide. The role of temozolomide rechallenge in this setting is unclear. Methods: This monocentric retrospective study included 70 patients with MGMT-methylated GBM, IDH wildtype, who received lomustine/temozolomide as first-line therapy. Descriptive data on second-line therapies were collected, and therapy responses were assessed. Survival outcomes were evaluated using Kaplan-Meier analysis. Results: Of 55 patients with documented tumor progression, 40 patients received second-line therapy. The most frequently used systemic therapy was temozolomide (n = 33, 79% of patients with second-line therapy), with a median number of 6 cycles and hematotoxicity grade 3 or 4 observed in <20% of patients. Among patients receiving temozolomide only, stable disease or partial response was achieved in 53.3%, with a progression-free survival rate at 6 months after first recurrence of 50% and a 1-year OS rate of 45%. Conclusions: Temozolomide rechallenge is a common, safe, and effective second-line option for patients with MGMT-methylated, IDH wildtype GBM following first-line lomustine/temozolomide therapy. These findings support its consideration as a salvage therapy in appropriate clinical scenarios.

8 September 2025 in Radiotherapy and Oncology
Verified
Journal Article
Open access
CDCas S. Dejonckheere
Cas S. Dejonckheere
Matthias SchneiderMatthias Schneider
Matthias Schneider
APAnna-Laura Potthoff
Anna-Laura Potthoff
MHMotaz Hamed
Motaz Hamed
DSDavide Scafa
Davide Scafa
JLJulian P. Layer
Julian P. Layer
In recent years, intraoperative radiotherapy (IORT) with low-energy X-rays is emerging as an alternative to postoperative stereotactic radiotherapy (SRT) of the resection cavity in patients with resectable brain metastases (BMs). We performed a systematic review of the MEDLINE, Embase, and Scopus databases, including all original articles on IORT for resectable BMs from 2015 to 2025. Data on safety, local control, and survival outcomes were collected. Ten records (5 prospective single-arm trials) were included, representing 261 patients (49 % lung primary) with a median follow-up (range) of 14 (0-79) months. 77 % of patients had a solitary BM at the time of surgery and IORT. The median applicator size was 2.0 cm and the median prescribed dose (range) 22.3 (20-30) Gy. The 1-year local control rate was 93 % and the 1-year distant brain control rate 48 %. Median overall survival was 19 months. Only 6 % of patients developed leptomeningeal disease and the cumulative rate of radiation necrosis was 2.6 % (grade 1 in 56 % of cases). The median time to next treatment beyond BM therapy (range) was 31 (1-136) days. This was significantly shorter compared to SRT control collectives. IORT for patients with BMs has a favorable toxicity profile and yields excellent local control. A potential advantage is the rapid completion of interdisciplinary BM treatment, allowing a swift transition to subsequent cancer treatments. A planned registry and a prospective randomized phase 3 trial will establish the preferred radiotherapy modality in the context of resectable BMs.

1 October 2024 in Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
TZThomas Zeyen
Thomas Zeyen
LBLaura Böhm
Laura Böhm
DPDaniel Paech
Daniel Paech
NSNiklas Schäfer
Niklas Schäfer
TTTheophilos Tzaridis
Theophilos Tzaridis
CSChristina Schaub
Christina Schaub
Background: Maximum tumor resection improves overall survival (OS) in patients with glioblastoma. The extent of resection (EOR) is historically dichotomized. The response assessment in neuro-oncology (RANO) resects group recently proposed criteria for volumetry-based EOR assessment in patients that were treated according to Stupp´s protocol. The purpose of this study was (1) to investigate the prognostic value of EOR in patients receiving combined chemotherapy with lomustine (CCNU)/temozolomide (TMZ), and (2) to analyze the prognostic performance of binary EOR assessment compared to volumetric assessment. Methods: Seventy-eight patients with newly diagnosed MGMT-methylated GBM undergoing tumor resection followed by radiochemotherapy with CCNU/TMZ were included in this study. Residual contrast-enhancing (CE) tumor volume after the first resection was measured and its influence on OS and progression-free survival was analyzed using uni- and multivariable Cox regression analysis as well as two-sided log-rank test. Patients were divided into residual tumor volume (RTV) ≤1 cm³, >1–≤5 cm³, and >5 cm³ following the proposed criteria of the RANO resect group. Results: Prolonged OS was associated with age <60 years, low RTV, and gross total resection. RTV had a superior prognostic value compared to binary EOR assessment. Patients with total or near total resection of CE tumor (≤ 1 cm³ RTV) showed prolonged OS (median 54.4 months, 95% CI: 46.94–not reached), with a 5-year survival rate of 49%. Conclusions: Low RTV is associated with increased survival in glioblastoma patients undergoing radiochemotherapy with CCNU/TMZ. This study demonstrates the applicability of the recently proposed RANO resect criteria in this subgroup of patients.

13 November 2025 in Neuro-Oncology
Verified
Journal Article
Open access
TZThomas Zeyen
Thomas Zeyen
IKInga Krause
Inga Krause
ADAndreas Decker
Andreas Decker
FKFlorian Kroh
Florian Kroh
SRSebastian Regnery
Sebastian Regnery
Daniel PaechDaniel Paech
Daniel Paech
Background: Differentiating progressive disease (PD) from treatment-related effects (TRE) in glioblastoma remains challenging, particularly at single time point evaluations. TRE can occur at any disease stage, and its underlying biology is poorly understood. This study evaluates the clinical feasibility and diagnostic performance of amide proton transfer-weighted (APTw) MRI in this challenge. Methods: Following the integration of APTw MRI into the routine clinical workflow for brain tumor imaging, we screened a total of 870 scans from 626 patients. APTw signal (voxel-based measurement) was automatically quantified in gadolinium-enhanced T1w and FLAIR regions of interest using a deep learning-based approach for 3D tumor segmentations. PD and TRE were compared using unpaired t-tests, and diagnostic accuracy was assessed via ROC- and logistic regression analysis. Results: Among 256 MRI scans of 143 patients with glioblastoma, 65 scans showed PD (n = 42) or TRE (n = 23). The median APTw signal was higher in PD (2.23%) vs TRE (1.76%; P = .001). ROC analysis showed an area under the curve (AUC) of 0.82. In patients with early PD or TRE (<6 months post-radiotherapy), the AUC increased to 0.93. Anti-angiogenic therapy decreased APTw signal (P < .01). Combining APTw MRI with DWI and PWI improved diagnostic accuracy (AUC = 0.90). Conclusions: APTw MRI is a non-invasive imaging tool that is feasible for clinical routine and aids in differentiation of early progression from pseudoprogression in glioblastoma. Its diagnostic accuracy decreases with application of anti-angiogenic treatment and at later follow-up time points. Highest diagnostic accuracy was found in a multimodal approach combining APTw MRI, PWI and DWI.